The intersection of viral infections and neurodegeneration continues to generate scientific debate, particularly around whether antiviral interventions might slow cognitive decline. Recent correspondence highlights methodological questions about a clinical trial testing valacyclovir, an antiviral medication commonly used for herpes infections, as a potential Alzheimer's treatment. The VALAD trial investigators are responding to concerns that participants' herpes zoster vaccination status may have influenced their study outcomes. The original trial examined whether valacyclovir could benefit patients with early symptomatic Alzheimer's disease, building on emerging evidence that viral infections might contribute to neurodegenerative processes. Critics point to epidemiological data showing that herpes zoster vaccination itself appears protective against dementia development, potentially creating a confounding variable in antiviral treatment studies. This methodological concern reflects broader challenges in Alzheimer's research where multiple interventions targeting similar biological pathways must be carefully controlled. The viral hypothesis of Alzheimer's disease has gained momentum as researchers identify herpes simplex virus DNA in brain tissue of deceased Alzheimer's patients and observe reduced dementia risk among antiviral users in population studies. However, translating these observational findings into effective treatments requires rigorous clinical trial design that accounts for all potential confounders. The correspondence underscores how vaccination history, medication interactions, and immune system variables can complicate interpretation of neurodegeneration trials. As the field moves toward combination therapies and precision medicine approaches, researchers must navigate increasingly complex interactions between infectious disease prevention and cognitive health interventions.